Epidemiological Description of the Kaposi’s Disease in France’s Southeast

Overview

The purpose of this study is to evaluate the prevalence of the Kaposi's disease in France's southeast on 10 years (from 2007 to 2017)

Full Title of Study: “Epidemiological Description of the Kaposi’s Disease in France’s Southeast”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: August 2020

Detailed Description

Kaposi's disease is a multifocal disease with cutaneous expression in more than 95% of cases. There are 4 forms : Mediterranean, Endemic (Sub-Saharan Africa), iatrogenic and epidemic (HIV) The physiological hypotheses to explain the disease are not clear. A proliferation of immunity cells in blood vessels and also an undetermined role of the human herpes virus 8 (HHV-8) could be involved. The treatment is complex and not standardized. There are a lot of different treatments. The purpose of this study is to evaluate the prevalence and described the characteristics and the treatment of the Kaposi's disease in the France's southeast on 10 years, from 2007 to 2017.

Clinical Trial Outcome Measures

Primary Measures

  • Prevalence of Kaposi’s disease
    • Time Frame: 10 years (2007-2017)
    • Diagnosed patients with biopsy, in France’s southeast

Secondary Measures

  • Descriptive analysis of the different form of the Kaposi’s disease in the population
    • Time Frame: 10 years (2007-2017)
    • Mediterranean form, endemic form, iatrogenic form and epidemic form
  • Descriptive analysis of the population : sociodemographic
    • Time Frame: 10 years (2007-2017)
    • sociodemographic characteristics
  • Descriptive analysis of the population : paraclinical
    • Time Frame: 10 years (2007-2017)
    • paraclinical characteristics
  • Descriptive analysis of the population : clinical
    • Time Frame: 10 years (2007-2017)
    • clinical characteristics
  • Descriptive analysis of the population : therapeutic
    • Time Frame: 10 years (2007-2017)
    • therapeutic care
  • Survival analysis
    • Time Frame: 10 years (2007-2017)
    • mortality rate

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosed patients with a Kaposi's disease by biopsy from January 2007 to December 2017 Exclusion Criteria:

  • Opposition to the use of personal data

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Direction Centrale du Service de Santé des Armées
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.